Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Age of patient when antidepressant(s) prescribed:

What condition was this medication prescribed to treat?

What additional medications were you taking at the time?

Did patient hurt themselves during or after taking the drug?

Did patient become violent during or after taking the drug?

Was suicide attempted?

Was hospitalization or institutionalization required after taking antidepressant(s)?

Did loved one commit suicide?

If patient did attempt or commit suicide, did patient ever attempt suicide previously?

If patient did commit suicide, what was the method of suicide?

Please describe violent or suicidal behavior:

If you ever tried to stop taking Paxil and experienced withdrawal, please describe the withdrawal side effects:

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

The Truth Behind Paxil’s Black Box

Jan 1, 2008 | Parker Waichman LLP

In "Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial", by Alison Bass, Bass details the deception and fraud by companies, doctors, and public officials involving Paxil and its serous side effects.  

In  Bass' story, Paxil—Big Drug—is at the heart of a tale that includes Big Pharma, which uses Big Money to urge Big Slick University Doctor  tomassage Big Drug trial data results while the Food & Drug Administration (FDA), partly funded Big Pharma, ignores everything.  Big Pharma is GlaxoSmithKline, Big Money includes an $800,000 research grant, and Big Slick University Doctor is Martin Keller of Brown University.

Paxil has long been known to cause suicidal thoughts in some children and causes more than just suicidal ideation in others, leading to suicide.  This was discovered in a clinical trial; however, the information was suppressed.  Glaxo continues to market Paxil, but a few insiders talked and, now, every prescription of every antidepressant must carry a black-box warning stating that these types of medications increase the risk of suicidal thinking and behavior in depressed children and adolescents.  As part of a settlement of a lawsuit brought by the attorney general of New York, Glaxo was required to disclose all results, including negative ones results, of all clinical drug trials.  Also, Congress has extended the mandate to the clinical trials of all drug makers.

Paxil also has a long history of difficult withdrawal side effects, causing patients to remain addicted to the drug.  As a matter-of-fact the British drug agency required Glaxo to remove a statement on its patient label saying it was not addictive.  Withdrawal effects are experienced just hours after a missed dose and include a "flu-like" syndrome, anxiety, dizziness, fatigue, headache, migraine-like feelings, nerves jangling when moving eyes, continuous indigestion, neck and back pain, psychotic features such as visual and/or audio hallucinations/illusions, insomnia, nausea, restlessness, "electrical shock" phenomena/electrical surges or shocks through the head and/or body, hyper-sensitivity of the nervous system to light, sound, colors and stressors, tremors, tinnitus and a vertiginous-like experience, depressive thoughts, suicidal thoughts, homicidal thoughts, extreme anger, severe agitation, extreme irritability, "over-reacting", ringing in ears and throbbing in head, vomiting, paranoia, aggressive behavior, roller-coaster emotions, out of character behavior, severe malaise, general dysphoria, derealization, and panic attacks.

A study linked these drugs to an increased risk of death among patients with coronary artery disease and the FDA is strengthening its warning for Paxil because it may be associated with birth defects, citing a study that found increased risk of fetuses developing heart defects.  The FDA asked Glaxo to reclassify Paxil, generically known as Paroxetine, as a "Category D" drug for pregnant women, which means that studies in pregnant women have shown a risk to the fetus.  The FDA is advising doctors not to prescribe Paxil to women in their first three months of pregnancy or people who are planning to become pregnant, unless there are no other options.

Related articles Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo